|Description||7ACC1 selectively interferes with lactate fluxes in the lactate-rich tumor microenvironment and inhibits lactate influx but not efflux in tumor cells expressing MCT1 and MCT4 transporters. It delayed the growth of cervix SiHa tumors, colorectal HCT116 tumors, and orthoptopic MCF-7 breast tumors and also inhibited SiHa tumor relapse after treatment with cisplatin. Besides, 7ACC did not prevent the cell entry of the substrate-mimetic drug 3-bromopyruvate (3BP) through MCT1, and contributed to the inhibition of tumor relapse after 3BP treatment.|
|Synonyms||DEAC; Coumarin D 1421; D 1421|
AR-C117977 is a potent MCT1 inhibitor that inhibited the rat MLR and was more potent than cyclosporin A (CsA). AR-C117977 can reduce vimmune responses both in v...
7ACC1 selectively interferes with lactate fluxes in the lactate-rich tumor microenvironment and inhibits lactate influx but not efflux in tumor cells expressing...
7ACC2 did not influence the prothrombin time which, together with a good in vitro ADME profile, supports the potential of this new family of compounds to act as...
AR-C155858 is a novel inhibitor of the monocarboxylate transporters (MCTs) MCT1 and MCT2, but exhibits no activity at MCT4. It can be used to probe MCTs’ roles ...
AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit M...
UK-5099 is a potent inhibitor of plasma membrane monocarboxylate transporters (MCTs) and the mitochondrial pyruvate carrier (MPC). It inhibits pyruvate-dependen...